James V. Caruso
Chief Executive Officer at CELLECTAR BIOSCIENCES, INC.
Net worth: 195 892 $ as of 2024-03-30
Profile
James V.
Caruso is the founder of Hip Innovation Technology LLC, which was founded in 2010.
He held the title of Director at the company starting in 2015.
He is currently the President, Chief Executive Officer & Director at Cellectar Biosciences, Inc., a position he has held since 2015.
In his former positions, Mr. Caruso served as the Senior Vice President-Sales & Marketing at Bone Care International, Inc. from 2002 to 2005.
From 2006 to 2010, he was the Chief Commercial Officer & Executive VP at Allos Therapeutics, Inc. He also held the position of Vice President-Neuroscience Specialty Sales at Novartis Corp.
from 2001 to 2002.
Prior to that, he was the Vice President-Sales at Knoll Pharmaceutical Co. from 2000 to 2001, and the Vice President-Primary & Specialty Sales at BASF Pharma Ltd.
from 2000 to 2001.
Mr. Caruso obtained his undergraduate degree from the University of Nevada.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-12-07 | 49,219 ( 0.40% ) | 195 892 $ | 2024-03-30 |
James V. Caruso active positions
| Companies | Position | Start |
|---|---|---|
| CELLECTAR BIOSCIENCES, INC. | Chief Executive Officer | 2015-06-14 |
| Hip Innovation Technology LLC | Founder | 2010-07-31 |
Former positions of James V. Caruso
| Companies | Position | End |
|---|---|---|
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Corporate Officer/Principal | 2010-08-23 |
Bone Care International, Inc.
 Bone Care International, Inc. Pharmaceuticals: OtherHealth Technology Bone Care International, Inc. developed innovative therapeutic products. Its products included Hectorol Injections and Capsules. The company was located in Middleton, WI. | Sales & Marketing | - |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Sales & Marketing | 2002-05-31 |
BASF Pharma Ltd.
 BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The private company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million. | Sales & Marketing | 2001-04-30 |
| Knoll Pharmaceutical Co. | Sales & Marketing | 2000-12-31 |
Training of James V. Caruso
| University of Nevada | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CELLECTAR BIOSCIENCES, INC. | Health Technology |
| Private companies | 6 |
|---|---|
Bone Care International, Inc.
Bone Care International, Inc. Pharmaceuticals: OtherHealth Technology Bone Care International, Inc. developed innovative therapeutic products. Its products included Hectorol Injections and Capsules. The company was located in Middleton, WI. | Health Technology |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
| Hip Innovation Technology LLC | |
BASF Pharma Ltd.
BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The private company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million. | Health Technology |
| Knoll Pharmaceutical Co. |
- Stock Market
- Insiders
- James V. Caruso
